Table 1 Baseline demographics and clinical characteristics: patients without ILD history using the most sensitive ILD definition
New anti-TNF Treatment episodes | New tocilizumab Treatment episodes | New rituximab Treatment episodes | New abatacept Treatment episodes | |
|---|---|---|---|---|
N = 7951 | N = 1528 | N = 1134 | N = 2683 | |
Female, n (%)a | 6462 (81.3) | 1267 (82.9) | 931 (82.1) | 2228 (83.0) |
Age, mean (SD)a | 51.7 (12.5) | 53.8 (12.0) | 53.8 (12.1) | 53.9 (12.6) |
Geographic region, n (%)a | ||||
Northeast | 1285 (16.2) | 230 (15.1) | 172 (15.2) | 393 (14.6) |
North Central | 1866 (23.5) | 382 (25.0) | 306 (27.0) | 686 (25.6) |
South | 3212 (40.4) | 583 (38.2) | 411 (36.2) | 1100 (41.0) |
West | 1536 (19.3) | 323 (21.1) | 235 (20.7) | 481 (17.9) |
Rural indicator, n (%)a, b | 1315 (16.5) | 225 (14.7) | 216 (19.0) | 392 (14.6) |
Medicare primary payer, n (%)a, b | 1001 (12.6) | 245 (16.0) | 195 (17.2) | 488 (18.2) |
Follow-up person years per patient, mean (SD) | 0.7 (0.6) | 0.7 (0.5) | 0.7 (0.5) | 0.7 (0.5) |
No of prior biologics, mean (SD)b, c | 1.4 (0.7) | 2.1 (1.1) | 1.9 (0.9) | 1.6 (0.8) |
Prior exposure to ≥2 biologics | 990 (12.5) | 715 (46.8) | 334 (29.5) | 198 (7.4) |
Prior exposure to ≥3 biologics | 186 (2.3) | 136 (8.9) | 40 (3.5) | 4 (0.1) |
RA medication history, n (%)d | ||||
Any anti-TNFα agentb | 5532 (69.6) | 617(40.4) | 571 (50.4) | 1865 (69.5) |
Methotrexate | 4293 (54.0) | 785 (51.4) | 604 (53.3) | 1361 (50.7) |
All other DMARDs | 2575 (32.4) | 531 (34.8) | 410 (36.2) | 883 (32.9) |
Prescription NSAIDs | 3407 (42.8) | 635 (41.6) | 449 (39.6) | 1080 (40.3) |
Glucocorticoid daily dosage, mean (SD)e | ||||
Noneb | 2307 (29.0) | 299 (19.6) | 214 (18.9) | 599 (22.3) |
<7.5 mg/day | 4355 (54.8) | 864 (56.5) | 642 (56.6) | 1534 (57.2) |
≥7.5 mg/dayb | 1285 (16.2) | 362 (23.7) | 278 (24.5) | 549 (20.5) |
Comorbid condition, n (%)f | ||||
Anemiab | 163 (2.1) | 45 (2.9) | 29 (2.6) | 52 (1.9) |
Asthma | 294 (3.7) | 76 (5.0) | 47 (4.1) | 118 (4.4) |
Cerebrovascular disease | 131 (1.6) | 20 (1.3) | 21 (1.9) | 44 (1.6) |
COPDb | 209 (2.6) | 59 (3.9) | 40 (3.5) | 92 (3.4) |
Diabetes | 845 (10.6) | 176 (11.5) | 150 (13.2) | 298 (11.1) |
Heart failure | 72 (0.9) | 23 (1.5) | 25 (2.2) | 38 (1.4) |
Hypertension | 1776 (22.3) | 372 (24.3) | 297 (26.2) | 663 (24.7) |
Ischemic heart diseaseb | 361 (4.5) | 81 (5.3) | 58 (5.1) | 143 (5.3) |
Pneumonia | 148 (1.9) | 34 (2.2) | 35 (3.1) | 74 (2.8) |
Any pulmonary condition other than ILDb | 600 (7.5) | 162 (10.6) | 112 (9.9) | 246 (9.2) |
Scleroderma | 15 (0.2) | 3 (0.2) | 7 (0.6) | 2 (0.1) |
Sjögren’s | 121 (1.5) | 32 (2.1) | 19 (1.7) | 51 (1.9) |
SLE | 122 (1.5) | 26 (1.7) | 37 (3.3) | 52 (1.9) |
Deyo-adapted CCI, mean (SD)f | 1.5 (1.0) | 1.6 (1.1) | 1.6 (1.2) | 1.6 (1.0) |